Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Consulting agrmnt
Inv. presentation
Appointed director
CC transcript
Neurotrope, Inc. (NTRP) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/07/2020 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failur...
Docs: "SEPARATION AND DISTRIBUTION AGREEMENT",
"TAX MATTERS AGREEMENT",
"Neurotrope and Metuchen Pharmaceuticals Announce Completion of Merger Forming Petros Pharmaceuticals"
11/25/2020 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
11/24/2020 8-K Other Events  Interactive Data
11/20/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Neurotrope, Inc. Approves Spin-Off of Neurotrope Bioscience, Inc. and Sets Record and Distribution Dates"
09/30/2020 8-K Quarterly results
09/30/2020 8-K Quarterly results
07/29/2020 8-K Quarterly results
07/24/2020 8-K Quarterly results
07/23/2020 8-K Quarterly results
05/28/2020 8-K Conference call transcript
Docs: "Conference Call Transcript held on May 28, 2020"
05/18/2020 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger and Reorganization, by and among Petros, Neurotrope, Merger Sub 1, Merger Sub 2 and Metuchen",
"Form of Neurotrope Voting Agreement, by and between Metuchen and certain stockholders of Neurotrope",
"Form of Metuchen Voting Agreement, by and between Neurotrope and certain unitholders of Metuchen",
"Form of Lock-Up Agreement, by and between Petros, Neurotrope, Metuchen and certain securityholders of Neurotrope and Metuchen",
"Consent of EisnerAmper LLP, Metuchen’ s independent registered public accounting firm",
"Neurotrope and Metuchen Pharmaceuticals Announce Merger Agreement to Form Petros Pharmaceuticals, a Men’ s Health Company",
"“Metuchen Business” section excerpt",
"“Metuchen Management’ s Disclosure and Analysis of Financial Condition and Results of Operations” section excerpt",
"“Risk Factors” section excerpt",
"“Fairness Opinion of Gemini Partners LLC” section excerpt"
05/11/2020 8-K Other Events
02/27/2020 8-K Quarterly results
02/26/2020 8-K Quarterly results
01/23/2020 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...
Docs: "Form of Series D Preferred Certificate of Designation",
"Form of Series H Common Stock Purchase Warrant",
"Opinion of Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C",
"Form of Securities Purchase Agreement",
"Consulting Advisory Agreement, by and between the Company and Katalyst Securities, LLC",
"Neurotrope, Inc. Announces $18 Million Registered Direct Offering"
01/22/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Neurotrope Provides Corporate Update After Completing Bryostatin-1 Data Analysis for Advanced Alzheimer’ s Disease Trial"
01/21/2020 8-K Other Events
10/25/2019 8-K Quarterly results
10/25/2019 8-K Quarterly results
09/09/2019 8-K Quarterly results
09/09/2019 8-K Quarterly results
08/05/2019 8-K Quarterly results
Docs: "Neurotrope Announces Corporate Update and Reports Second Quarter 2019 Financial Results"
07/24/2019 8-K Submission of Matters to a Vote of Security Holders
04/01/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Agreement, between Neurotrope, Inc. and Michael Ciraolo",
"NEUROTROPE APPOINTS DR. MICHAEL CIRAOLO AS GENERAL COUNSEL AND CHIEF OPERATING OFFICER NEW YORK, April 1, 2019 – Neurotrope, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’ s disease , announced today that Michael Ciraolo, J.D., Ph.D., is joining the Company as general counsel and chief operating officer. "I am very pleased to welcome Michael to the Neurotrope executive management team," said Charles Ryan, Neurotrope’ s chief executive officer. "He is an exceptional leader and lawyer and we expect will prove instrumental as we continue to execute at this important point in the Company’ s evolution. We look forward to reporting top-line data from our current Phase 2 confirmatory clinical trial in the second ha..."
12/31/2018 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Amendment to Placement Agent Agreement, by and between the Company and GP Nurmenkari Inc",
"Amendment to Advisory Consulting Agreement, by and between the Company and Maxim Group LLC",
"Amendment to Advisory Consulting Agreement, by and between the Company and Katalyst Securities LLC"
12/17/2018 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Departure of Directors or Certain Office...
Docs: "Form of Series G Common Stock Purchase Warrant",
"Opinion of Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C",
"Form of Securities Purchase Agreement",
"Form of Consulting Agreement",
"Placement Agent Agreement, by and between the Company and GP Nurmenkari Inc",
"Neurotrope Announces $22.5 Million Registered Direct Offering"
12/14/2018 8-K Submission of Matters to a Vote of Security Holders
12/04/2018 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Form of Second Amendment to Amended and Restated Technology License and Services Agreement among Neurotrope BioScience, Inc., Cognitive Research Enterprises, Inc. and NRV II, LLC"
09/05/2018 8-K Other Events
06/22/2018 8-K Resignation/termination of a director
05/10/2018 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Services Agreement by and between Worldwide Clinical Trials, Inc. and Neurotrope BioScience Inc."
01/08/2018 8-K Investor presentation
Docs: "January 2018 Investor Presentation"
12/18/2017 8-K Appointed a new director
Docs: "Separation Agreement, between Neurotrope, Inc., Neurotrope Bioscience, Inc. and Susanne Wilke, Ph.D",
"Employment Agreement, between Neurotrope, Inc. and Charles Ryan",
"Neurotrope Appoints Charles S. Ryan as Chief Executive Officer"
10/19/2017 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy